Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast cancer highlights from ESMO 2018

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium
Breast cancer highlights from ESMO 2018 ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )
12 Nov 2018

Editor’s Choice for October 2018

Prof Gordon McVie - Founding Editor, ecancer
Editor’s Choice for October 2018 ( Prof Gordon McVie - Founding Editor, ecancer )
1 Nov 2018

The IMpower-132 trial for non small cell lung cancer

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US
The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )
29 Oct 2018

ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma

Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma ( Prof Paolo Ascierto -  Istituto Nazionale Tumori, Milan, Italy )
29 Oct 2018

Keynote lecture: Mutation signatures and targeting the DNA damage response

Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK
Keynote lecture: Mutation signatures and targeting the DNA damage response ( Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK )
29 Oct 2018

Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma

Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands
Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma ( Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands )
29 Oct 2018

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )
29 Oct 2018

Modern melanoma treatment in the UK

Dr Joseph Sacco - University of Liverpool, Liverpool, UK
Modern melanoma treatment in the UK ( Dr Joseph Sacco - University of Liverpool, Liverpool, UK )
26 Oct 2018

Latest advances in treatment for ALK positive NSCLC

Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie,  Dr Lázaro Quintela )
26 Oct 2018

The case for biosimilars

Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The case for biosimilars ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
26 Oct 2018

Highlights in early non-metastatic NSCLC and thoracic tumours

Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )
26 Oct 2018